Late-stage results Otsuka presented in IgA nephropathy triggered a sell-off in Vera shares. Elsewhere, investors scrutinized ...

A deal worth up to $712 million with the China-based biotech gives Cullinan T cell engagers aimed at BCMA and CD19, two ...

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...

The company is one of the first to receive a “platform technology designation,” which could speed the review of certain gene ...

Enhertu, Datroway and other antibody-drug conjugates developed by Daiichi Sankyo have made the company a leader in a ...

The investment bank says funding was down 57% last month, to $2.7 billion, and argues the new administration’s FDA ...

Elinzanetant proved effective for managing disruptive vasomotor symptoms in women on endocrine therapy, supporting a Bayer ...

According to J&J, Akeega is the first PARP inhibitor combination that’s proven effective treating earlier-stage prostate ...

Antibody drugs that target the PD-1 and VEGF pathways are in the ASCO spotlight, while doctors wrestle with how to use new ...

The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

The shot, dubbed mNexspike, is approved for older adults and people whose health conditions put them at higher risk of severe ...